logo
Plus   Neg
Share
Email

Ryder System Provides Q1, FY19 - Quick Facts

Ryder System, Inc. (R) on Thursday initiated earnings and revenue guidance for the first quarter of fiscal 2019 and the full-year-2019.

The company now projects earnings in a range of $5.18 to $5.48 per share, comparable earnings in a range of $6.00 to $6.30 per share and comparable earnings, excluding new lease accounting standard in a range of $6.20 to $6.50 per share.

Total revenue for the full-year 2019 is forecast to be up 8 percent to about $9 billion and operating revenue to be up 9 percent to about $7 billion.

On average, analysts polled by Thomson Reuters expect the company to earn $6.14 per share on revenue growth of 6.3 percent to $8.87 billion for the year. Analysts' estimates usually exclude special items.

For the first quarter of fiscal 2019, the company expects earnings in a range of $0.71 to $0.78 per share, comparable earnings in a range of $0.96 to $1.03 per share and comparable earnings, excluding new lease accounting standard in a range of $0.94 to $1.01 per share. Analysts are looking for earnings of $1.02 per share for the quarter.

Ryder said it will adopt a new lease accounting standard effective January 1, 2019, which has no impact on cash flow or total earnings over the life of a lease contract. The new standard, however, changes the timing of revenue recognition to better align with maintenance costs. The 2019 forecast for earnings per share was lowered by about $0.20 to reflect this standard.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT